Kinetics of Procalcitonin in Pediatric Patients on Extracorporeal Membrane Oxygenation

Objectives: To assess the kinetics of procalcitonin (PCT) and C-reactive protein (CRP) in pediatric patients who required extracorporeal membrane oxygenation (ECMO) and to analyze its relationship with morbidity and mortality. Patients and methods: Prospective observational study including pediatric...

Full description

Saved in:
Bibliographic Details
Published in:Biomarker Insights 2018, Vol.13, p.1177271917751900-1177271917751900
Main Authors: Bobillo, Sara, Rodríguez-Fanjul, Javier, Solé, Anna, Moreno, Julio, Balaguer, Mònica, Esteban, Elisabeth, Cambra, Francisco José, Jordan, Iolanda
Format: Article
Language:English
Subjects:
Antibiotics
Authorship
Bacterial infections
Biomarkers
C-reactive protein
Evolution
Intensive care
Medical prognosis
Morbidity
Mortality
Multiple organ dysfunction syndrome
Neurological complications
Nosocomial infections
Oxygenation
Patients
Pediatrics
Procalcitonin
Respiratory therapy
Review
Sepsis
Statistical analysis
Studies
Values
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives: To assess the kinetics of procalcitonin (PCT) and C-reactive protein (CRP) in pediatric patients who required extracorporeal membrane oxygenation (ECMO) and to analyze its relationship with morbidity and mortality. Patients and methods: Prospective observational study including pediatric patients who required ECMO. Both PCT and CRP were sequentially drawn before ECMO (P0) and until 72 hours after ECMO. Results: A total of 40 patients were recruited. Two cohorts were established based on the value of the P0 PCT (>10 ng/mL). Comparing the kinetics of PCT and CRP in these cohorts, the described curves were the expected for each clinical situation. The cutoff for P0 PCT to predict multiple organ dysfunction syndrome was 2.55 ng/mL (sensibility 83%, specificity 100%). Both PCT and CRP did not predict risk of neurologic sequelae or mortality in any group. Conclusions: Procalcitonin does not seem to be modified by ECMO and could be a good biomarker of evolution.
ISSN:1177-2719
1177-2719
DOI:10.1177/1177271917751900